Loading...
 
Translate Register Log In Login with facebookLogin and Register

Psychosis risk reduced for 80 weeks by just 12 weeks of Omega-3 – RCT Aug 2017

Predictors of longer-term outcome in the Vienna omega-3 high-risk study

Schitophrenia Research, DOI: http://dx.doi.org/10.1016/j.schres.2017.08.010
Nilufar Mossahebr, Nilufar Mossaheb, Nilufar Mossaheb, Miriam R. Schäfer, Miriam R. Schäfer, Monika Schlögelhofer Monika Schlögelhofer, Claudia M. Klier, Claudia M. Klier, Stefan . . .

VitaminDWiki

Image
Overview Schizophrenia and Vitamin D contains the following summary

Many reasons to think that schizophrenia is associated with low vitamin D
1) 97% of patients with schizophrenia are vitamin D deficient
2) Schizophrenia varies with latitude (UVB) by 10X (controversy)
3) Schizophrenia is more common in those with dark skin (when away from the equator)
4) Schizophrenia is associated with low natal vitamin D
5) Schizophrenia has been increasing around the world when vitamin D has been decreasing (controversy)
6) Schizophrenia is associated with low birth rate, which is associated with low vitamin D
7) Schizophrenia is associated with Autism which is associated with low vitamin D
8) Schizophrenia Bulletin Editorial (Jan 2014) speculated that Vitamin D could be a major player
9) Schizophrenia 2X more likely if low vitamin D - meta-analysis
10) Schizophrenia increased 40 % for Spring births after Danes stopped vitamin D fortification
11) Schizophrenia is associated with season of birth
12) Schizophrenia is associated with poor Vitamin D Receptor genes
13) Schizophrenia risk is decreased if give Vitamin D after birth
    Click here for some details
Omega-3 may treat schizophrenia wonder if Omega-3 and Vitamin D would be additive or even synergistic

Items in BOTH of the categories Cognition and Omega-3


Longer-term data on ω-3 polyunsaturated fatty acids (PUFA) for prevention of psychosis in (ultra high risk) UHR individuals have initially shown promising results.

This analysis aimed to assess clinical predictors of longer-term outcome in UHR individuals treated with ω-3 PUFAs versus placebo.

Data derived from an RCT in 81 UHR individuals treated with ω-3 PUFAs versus placebo for 12 weeks and follow-up assessment after a median of 6.7 years.

Baseline GAF, baseline PANSS global score, pre-to-post-intervention change in EPA (Eicosapentaenoic acid) level were significant predictors of transition to psychosis, PANSS negative score and baseline MADRS reached trend-levels. In the final multivariate Cox regression analysis change in EPA levels remained the only significant predictor.

Taking into account all other significant predictors, changes in EPA levels were found to be the single most significant predictor for transition to psychosis in a longer term observation of UHR individuals.

Publisher wants $36 for the details in the PDF

Created by admin. Last Modification: Tuesday June 19, 2018 21:17:13 GMT-0000 by admin. (Version 6)
See any problem with this page? Report it (FINALLY WORKS)